Herantis Pharma Oyj

HRTIS.HE

Biotechnology · Healthcare

Exchange

NASDAQ Helsinki

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Herantis Pharma Oyj is a small Finnish biotechnology company focused on developing experimental drugs for serious neurological diseases. Its main programs target Parkinson's disease and dry eye disease, with the goal of finding treatments that could slow or stop disease progression rather than just managing symptoms. The company does not yet sell any approved products and is in the clinical trial stage.

Herantis generates no product revenue and funds its operations primarily through equity raises and grants, which is typical for early-stage biotech companies. It is headquartered in Helsinki, Finland, and operates at a significant loss, as reflected in its deeply negative returns. The company's entire value depends on whether its drug candidates succeed in clinical trials — if trials fail or funding runs out, the business faces serious risk of not surviving, making this a high-risk, speculative-stage investment.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-27.3% YoY

YoY Growth Rate

Earnings declining

Insider Activity

34.3%ownership

Insiders own a meaningful stake in the company

Cash Runway

~1 months

€3M cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Cash watch

Herantis Pharma Oyj has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial